Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Edward M Messing

Showing results (181-190 of 199) with videos related to

Pageof 20
Sort By:
Journal of the National Cancer Institute|April 5, 2007
Promotion of bladder cancer development and progression by androgen receptor signalsHiroshi Miyamoto, Zhiming Yang, Yei-Tsung Chen, et al.
Urologic Oncology|May 5, 2010
BCAN Think Tank session 3: Prevention of bladder cancerSeth P Lerner, H Barton Grossman, Edward M Messing, et al.
The Journal of Urology|October 27, 2012
Diagnosis, evaluation and follow-up of asymptomatic microhematuria (AMH) in adults: AUA guidelineRodney Davis, J Stephen Jones, Daniel A Barocas, et al.
European Urology|December 4, 2019
Non-visible haematuria for the Detection of Bladder, Upper Tract, and Kidney Cancer: An Updated Systematic Review and Meta-analysisIbrahim Jubber, Shahrokh F Shariat, Samantha Conroy, et al.
The Prostate|April 23, 2002
Generation of monoclonal antibodies specific for human kallikrein 2 (hK2) using hK2-expressing tumorsTerrence L Fisher, MaryAnn Nocera, Richard A Willis, et al.
The Journal of Urology|October 10, 2019
Local Recurrence Following Resection of Intermediate-High Risk Nonmetastatic Renal Cell Carcinoma: An Anatomical Classification and Analysis of the ASSURE (ECOG-ACRIN E2805) Adjuvant TrialZiho Lee, Opeyemi A Jegede, Naomi B Haas, et al.
Clinical Genitourinary Cancer|July 23, 2022
Risk-Based Assessment Of the Impact Of Intravesical Therapy on Recurrence-Free Survival Rate Following Resection of Suspected Low-grade, Non-muscle-invasive Bladder Cancer (NMIBC): A Southwest Oncology Groups (SWOG) S0337 Posthoc AnalysisNicholas J Corsi, Edward M Messing, Akshay Sood, et al.
BJU International|November 26, 2010
Do mixed histological features affect survival benefit from neoadjuvant platinum-based combination chemotherapy in patients with locally advanced bladder cancer? A secondary analysis of Southwest Oncology Group-Directed Intergroup Study (S8710)Emil Scosyrev, Benjamin W Ely, Edward M Messing, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 20, 2019
Predicting Renal Cancer Recurrence: Defining Limitations of Existing Prognostic Models With Prospective Trial-Based ValidationAndres F Correa, Opeyemi Jegede, Naomi B Haas, et al.
Radiology|November 1, 2002
CT in detecting urinary tract calculi: influence on patient imaging and clinical outcomesRonald H Gottlieb, Thao Christine La, Erdal N Erturk, et al.
Pageof 20

Showing results (181-190 of 199) with videos related to

Sort By:
Pageof 20
Journal of the National Cancer Institute|April 5, 2007
Promotion of bladder cancer development and progression by androgen receptor signalsHiroshi Miyamoto, Zhiming Yang, Yei-Tsung Chen, et al.
Urologic Oncology|May 5, 2010
BCAN Think Tank session 3: Prevention of bladder cancerSeth P Lerner, H Barton Grossman, Edward M Messing, et al.
The Journal of Urology|October 27, 2012
Diagnosis, evaluation and follow-up of asymptomatic microhematuria (AMH) in adults: AUA guidelineRodney Davis, J Stephen Jones, Daniel A Barocas, et al.
European Urology|December 4, 2019
Non-visible haematuria for the Detection of Bladder, Upper Tract, and Kidney Cancer: An Updated Systematic Review and Meta-analysisIbrahim Jubber, Shahrokh F Shariat, Samantha Conroy, et al.
The Prostate|April 23, 2002
Generation of monoclonal antibodies specific for human kallikrein 2 (hK2) using hK2-expressing tumorsTerrence L Fisher, MaryAnn Nocera, Richard A Willis, et al.
The Journal of Urology|October 10, 2019
Local Recurrence Following Resection of Intermediate-High Risk Nonmetastatic Renal Cell Carcinoma: An Anatomical Classification and Analysis of the ASSURE (ECOG-ACRIN E2805) Adjuvant TrialZiho Lee, Opeyemi A Jegede, Naomi B Haas, et al.
Clinical Genitourinary Cancer|July 23, 2022
Risk-Based Assessment Of the Impact Of Intravesical Therapy on Recurrence-Free Survival Rate Following Resection of Suspected Low-grade, Non-muscle-invasive Bladder Cancer (NMIBC): A Southwest Oncology Groups (SWOG) S0337 Posthoc AnalysisNicholas J Corsi, Edward M Messing, Akshay Sood, et al.
BJU International|November 26, 2010
Do mixed histological features affect survival benefit from neoadjuvant platinum-based combination chemotherapy in patients with locally advanced bladder cancer? A secondary analysis of Southwest Oncology Group-Directed Intergroup Study (S8710)Emil Scosyrev, Benjamin W Ely, Edward M Messing, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 20, 2019
Predicting Renal Cancer Recurrence: Defining Limitations of Existing Prognostic Models With Prospective Trial-Based ValidationAndres F Correa, Opeyemi Jegede, Naomi B Haas, et al.
Radiology|November 1, 2002
CT in detecting urinary tract calculi: influence on patient imaging and clinical outcomesRonald H Gottlieb, Thao Christine La, Erdal N Erturk, et al.
Pageof 20